Lilly’s ‘triple G’ agonist triumphs in Phase III trial, but AEs unnerve analysts

Lilly's retatrutide may have the best weight loss efficacy so far, but analysts are concerned around its tolerability compared with tirzepatide. While retatrutide may have the best weight loss efficacy to date, analysts hold concerns about its tolerability profile compared with best-seller, tirzepatide. Lilly’s retatrutide demonstrated significant weight loss, though analysts have raised concerns around the high discontinuation rates in the 12mg cohort. Credit: M7Studio / Shutterstock.com. Eli Lilly’s ‘triple G’ agonist, retatrutide, has secured another late-stage win in obesity, though analysts question whether the drug will outcompete the company’s market-leading medication, tirzepatide. In the Phase III TRIUMPH-1 study (NCT05929066)…

Source: Clinical Trials Arena